Last month, Axplora participated in CPHI Worldwide, the unmissable annual event for global players in the pharmaceutical industry.
Let’s get back to this successful CPHI Barcelona 2023 edition in video with an exclusive interview from Dr. Sylke Hassel, led by Life Sciences Knowledge Hub, to discuss the key achievements, forces and breaking news of Axplora:
- Axplora’s broad and strong network of sites, with a global footprint both in Europe and India to answer all customers’ needs and serve patients worldwide.
- The appointment of Dr. Stephan Haitz as Novasep CDMO BU President, and Dr. Pere Paton as Chief Operations Officer, to reinforce Axplora’s position as a leader in the CDMO market.
- The introduction of the newly formed Scientific Advisory Board (SAB): five industry leaders in API development and manufacturing expertise such as Flow chemistry, Electrochemistry, Steroids, Biotechnology and Antibody Drug Conjugates (ADCs).
https://www.youtube.com/watch?v=mvg1cGAnPzw&t=187s
A year after the merger between Farmabios, Novasep and PharmaZell under the single brand Axplora, CPHI was the unique opportunity to look back over our first few months as a group. A wonderful anniversary for the brand and the teams working hard behind, with promising meetings and fruitful discussions. A great outlook for the future!
Latest news
News
July 09, 2026
Axplora’s European CDMO network raises the bar with enhanced EcoVadis ratings across four manufacturing sites
Axplora’s Leverkusen site was awarded Platinum, with Le Mans receiving Gold, and Pompey and Chasse-sur-Rhône Silver in their first individual EcoVadis assessments. Recognition reinforces Axplora’s commitment to helping customers navigate increasingly complex supply chains with confidence through responsible, transparent and reliable manufacturing. 9 July, 2026 – Axplora, a global CDMO Partner for complex […]
News
June 10, 2026
Axplora consolidates UDCA manufacturing at Vizag site to strengthen integrated global supply and support future growth
Move reinforces Axplora’s integrated API supply model, expands critical manufacturing capabilities in India and enables Farmabios to sharpen focus on Steroids and HPAPI leadership June 10th, 2026 – Axplora, a global leader in the manufacturing of small molecule APIs and ADCs for the pharmaceutical industry, today announced the strategic consolidation of ursodeoxycholic acid (UDCA) manufacturing at its Vizag, India site, part of the PharmaZell business unit. Production will transition fully from the […]
News
March 17, 2026
Biopharma’s Growing Emphasis on Highly Potent Drugs Drives Axplora Manufacturing Expansion
Highly potent drugs now account for over 30% of the global pipeline, with more than 1,000 molecules in development — Axplora’s investments in HPAPI capacity help customers bring these complex therapies to market faster $60 million investment to expand highly potent API (HPAPI) development and manufacturing at Axplora’s Farmabios site in Gropello Cairoli, Italy New […]
We enable our partners to fully realize their ambitions.
Driven by the curiosity, skills and dedication of over 2,000 employees on three continents, Axplora delivers sustainable, technologically advanced API solutions to improve lives worldwide.